AN ACT relating to prescription drugs; directing the Legislative Commission to appoint a committee to conduct an interim study concerning the costs of prescription drugs in this State; and providing other matters properly relating thereto.

Legislative Counsel’s Digest:

This bill directs the Legislative Commission to appoint a committee to conduct an interim study concerning the issue of the costs of prescription drugs in this State and the impact of rebates, reductions in price and other remuneration from drug manufacturers on prescription drug prices.

EXPLANATION – Matter in bolded italics is new; matter between brackets [omitted material] is material to be omitted.

THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

Sections 1-24. (Deleted by amendment.)

Sec. 25. 1. The Legislative Commission shall appoint a committee to conduct an interim study concerning the cost of prescription drugs in this State and the impact of rebates, reductions in price and other remuneration from manufacturers on prescription drug prices.

2. The interim committee must be composed of six Legislators as follows:
   (a) Two members appointed by the Majority Leader of the Senate;
   (b) Two members appointed by the Speaker of the Assembly;
   (c) One member appointed by the Minority Leader of the Senate; and
   (d) One member appointed by the Minority Leader of the Assembly.

3. The Legislative Commission shall appoint a Chair and Vice Chair from among the members of the interim committee.

4. In conducting the study, the interim committee shall consult with and solicit input from persons and organizations with expertise in matters relevant to the costs of prescription drugs and the impact of rebates, reductions in price and other remuneration from manufacturers on prescription drug prices.

5. The interim committee shall study and examine:
   (a) The overall costs of prescription drugs in this State, including, without limitation, a comparison of those costs with other states;
(b) The impact of rebates, reductions in price and other remuneration from manufacturers on the overall costs of prescription drugs in this State; and
(c) Opportunities and options for lowering the costs of prescription drugs to make those drugs more affordable for the residents of this State.

6. The Legislative Commission shall submit a report of the results of the study, including any recommendations for legislation to:

   (a) The Legislative Committee on Health Care; and
   (b) The Director of the Legislative Counsel Bureau for transmittal to the 81st Session of the Nevada Legislature.

7. As used in this section, “manufacturer” has the meaning ascribed to it in NRS 639.009.

Sec. 26. This act becomes effective on July 1, 2019.